Hwaryun Lee
Ewha Womans University · Medicine
About the Lab
Professor Hwaryun Lee's research lab specializes in translational oncology, focusing on the development and evaluation of novel nanotherapeutics for advanced and metastatic cancers. The lab conducts rigorous clinical research, particularly meta-analyses of randomized controlled trials, to assess the efficacy and safety of innovative chemotherapy agents such as nanoparticle albumin-bound (nab)-paclitaxel in breast cancer treatment. A key research direction involves comparing nab-paclitaxel with conventional solvent-based taxanes to optimize first-line therapy outcomes in metastatic breast cancer. The lab also investigates the impact of changing regulatory approvals—such as the withdrawal of bevacizumab—on treatment paradigms and patient outcomes.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
1The curative effects of nanoparticle albumin-bound (nab)-paclitaxel in the first-line treatment of metastatic breast cancer (MBC) are still controversial, with even more after the removal of marketing approval of indication of bevacizumab. Five electronic databases and the related resources were searched for eligible randomized clinical trials (RCTs) without year and language restrictions to perform a meta-analysis. The studies were comparing the efficacy and safety between nab-paclitaxel chemot
Research Areas
Dive deeper into Hwaryun Lee's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.